Study design
SECONDARY
We conducted a phase 1 open-label study using three cohorts with increasing doses of BPG, with the primary objective of assessing the safety and tolerability of SCIP. The secondary objectives were to characterize the PK, including the time above the current accepted pharmacological surrogate for protection against 